

SCIENTIFIC PUBLICATIONS

CHRONOLOGICAL LIST

Frank M. Berger, M.D.

SCIENTIFIC PUBLICATIONS

CHRONOLOGICAL LIST

Frank M. Berger, M.D.

1. Besonders hohe Wirksamkeit des Follikelhormons bei vaginaler Installation. (The particularly high efficacy of the female sex hormone on vaginal administration). *Klinische Wochenschrift* 14:1601-1602, November 9, 1935.
2. Ein Beitrag zur Bakteriophagentherapie der Zystitis. (A contribution to the treatment of cystitis by bacteriophage.) *Zentralblatt für Bakteriologie Abt. I Orig.* 137:360-362, October 6, 1936.
3. Fortgesetzte Studien über vaginale Anwendung des Follikelhormons. (Continued investigations concerning the vaginal administration of estrogenic hormone.) *Klinische Wochenschrift* 16:1428-1431, October 9, 1937.
4. Ueber die Möglichkeit einer lokalen Steigerung der Kurzwellenwirkung (with G. Brecher). (Concerning the local intensification of short wave effects). *Weiner Klinische Wochenschrift* 51:1129-1131, October 14, 1938.
5. A slide agglutination test for the exclusion and diagnosis of typhoid fever (with G. Brecher), *Journal of Hygiene* 39:294-297, May 1939.
6. An agglutination test for the serological diagnosis of syphilis, *Journal of Pathology and Bacteriology* 55:363-371, July 1943.
7. Clumping of pathogenic staphylococci in plasma, *Journal of Pathology and Bacteriology* 55:435-440, October 1943.
8. The sensitizing and indicator action of Victor blue and Janus green on the flocculation reaction for syphilis, *British Journal of Experimental Pathology* 24:252-260, December 1943.
9. The incidence and causes of discrepancies in the results of serological tests for syphilis (with P.L. Sutherland), *Journal of Pathology and Bacteriology* 56:237-246, April 1944.
10. A milk-borne outbreak of gastroenteritis due to *Salmonella dublin* (with P.L. Sutherland), *British Medical Journal* 1:488-490, April 8, 1944.

11. A procedure for the serological diagnosis of syphilis based on a comparative study of five modern serological tests (with G. Denton), *British Journal of Venereal Diseases* 20:118-123, September 1944.
12. Extraction and purification of penicillin, *Nature (London)* 154:459, October 7, 1944.
13. Preparation of purified penicillin, *British Medical Journal* 1:116-117, January 27, 1945.
14. A new non-mannite-fermenting dysentery organism of the Flexner group, *Journal of Hygiene* 44:116-119, April 1945.
15. Properties, preparation and clinical application of penicillin, *Compendium of the Czechoslovak Medical Association in Great Britain* 1:3-10, June 1945.
16. The pharmacological properties of alpha, beta-dihydroxy-gamma-(2-methylphenoxy)-propane (myanesin) (with W. Bradley), *British Journal of Pharmacology and Chemotherapy* 1:265-272, December 1946.
17. The comparative value of arachis oil with beeswax and ethyl oleate with beeswax in delaying absorption of penicillin, *Quarterly Journal of Pharmacy and Pharmacology* 20:22-27, January-March 1947.
18. The muscle-relaxing action of myanesin (with W. Bradley), *Lancet* 1:97, January 18, 1947.
19. The effect of analeptic and other substances on the paralysing action of myanesin, *Quarterly Journal of Pharmacy and Pharmacology* 20:94-99, April-June 1947.
20. Muscle-relaxing ethers of glycerol (with W. Bradley), *Nature (London)* 159:813-814, June 14, 1947.
21. The mode of action of myanesin, *British Journal of Pharmacology and Chemotherapy* 2:241-250, December 1947.
22. For and against myanesin, *Lancet* 1:651, April 24, 1948.
23. Oral myanesin in the treatment of spastic and hyperkinetic disorders (with R. P. Schwartz), *Journal of the American Medical Association* 137:772-774, June 26, 1948.

24. The toxicity and muscular effect of d-tubocurarine combined with beta-erythroidine, myanesin or evipal (with R. P. Schwartz), *Journal of Pharmacology and Experimental Therapeutics* 93:362-367, July 1948.
25. The relationship between chemical structure and central depressant action of substituted ethers of glycerol, *Journal of Pharmacology and Experimental Therapeutics* 93:470-481, August 1948.
26. The pharmacological properties of some 2-substituted-4-hydroxy-methyl-1,3-dioxolanes (with V. Boekelheide and D. S. Tarbell), *Science* 108:561-562, November 19, 1948.
27. Metabolism of myanesin (3-(*o*-toloxy)-1,2-propanediol) (with R. F. Riley), *Archives of Biochemistry* 20:159-160, January 1949.
28. Paralyzing action of 2-methyl,2-n-amyl-hydroxy-methyl-1,3-dioxolane (glyketal), *Federation Proceedings* 8:274, March 1949.
29. Preparation and pharmacological properties of the acid succinate of myanesin (with R.F. Riley), *Federation Proceedings* 8:328, March 1949.
30. Anticonvulsant action of 2-substituted-1,3-propanediols, *Proceedings of the Society for Experimental Biology and Medicine* 71:270-271, June 1949.
31. The conversion of beta-erythroidine to derivatives of the desmethoxy series and some of the pharmacological properties of apo-beta-erythroidine (with G. L. Sauvage and V. Boekelheide), *Science* 109:627-628, June 24, 1949.
32. The pharmacological properties of 2-methyl, 2-n-amyl-4-hydroxy-methyl-1, 3-dioxolane (glyketal), a new blocking agent of interneurons, *Journal of Pharmacology and Experimental Therapeutics* 96:213-223, July 1949.
33. The preparation and pharmacological properties of the acid succinate of 3-(*o*-toloxy)-1,2-propanediol (myanesin) (with R. F. Riley), *Journal of Pharmacology and Experimental Therapeutics* 96:269-275, July 1949.
34. Spinal cord depressant drugs, *Pharmacological Reviews* 1(2):243-278, August 1949 and *Journal of Pharmacology and Experimental Therapeutics* 96 (Part II):243-278, August 1949.
35. The treatment of paralysis agitans with thephorin, *New York State Journal of Medicine* 49:1817-1820, August 1, 1949.
36. Haemolytic effects of myanesin, *Lancet* 1:90, January 14, 1950.

37. Pharmacological properties of 2,2-diethyl-1,3-propanediol (DEP) (with B. J. Ludwig and C. Russo), *Federation Proceedings* 9:258, March 1950.
38. The anticonvulsant action of 2,2-diethyl-1,3-propanediol (DEP) and some of its homologues and esters (with B. J. Ludwig), *Journal of Pharmacology and Experimental Therapeutics* 100:27-37, September 1950.
39. Paralyzing and anticonvulsant properties of substituted n-propyl-o-tolyl ethers (with B. J. Ludwig), *Journal of Pharmacology and Experimental Therapeutics* 101:2, January 1951.
40. The paralyzing activity of some substituted dioxolanes in relation to their structure, *Archives Internationales de Pharmacodynamie et de Therapie* 85:474-483, February 1951.
41. Anticonvulsant activity 2,2-disubstituted-1,3-propanediols in electroshock seizures, *Proceedings of the Society for Experimental Biology and Medicine* 78:277-279, October 1951.
42. A new nitrogen free, hypo-allergenic antipruritic (with O. J. Sokoloff), *Journal of the Medical Society of New Jersey* 49:23-25, January 1952.
43. Cation exchange properties of alginic acid (with B. J. Ludwig and W. T. Holfeld), *Proceedings of the Society of Experimental Biology and Medicine* 79:176-179, January 1952.
44. The anticonvulsant activity of carbamate esters of certain 2,2-disubstituted-1,3-propanediols, *Journal of Pharmacology and Experimental Therapeutics* 104:229-233, February 1952.
45. Medicinal uses of alginic acid (B. J. Ludwig), *Federation Proceedings* 11:322, March 1952.
46. The central depressant properties of α -toloxypropyl carbamates, *Journal of Pharmacology and Experimental Therapeutics* 104:468-473, April 1952.
47. Central depressant and anticonvulsant properties of glycerol ethers isomeric with mephenesin, *Journal of Pharmacology and Experimental Therapeutics* 105:450-457, August 1952.
48. The hydrophylic and acid binding properties of alginates with (with B. J. Ludwig and K. H. Wielich), *American Journal of Digestive Diseases* 20:39-42, February 1953.

49. The analeptic action of 1-*n*-butylamino-3-*p*-toluidino-2-propanol (W181) in mephenesin paralysis, *Journal of Pharmacology and Experimental Therapeutics* 107:250-257, February 1953.
50. The action of mephenesin on body temperature (with T. E. Lynes), *Federation Proceedings* 12:345, March 1953.
51. Hemolytic action of water soluble compounds related to mephenesin (with C. V. Hubbard and B. J. Ludwig), *Proceedings of the Society for Experimental Biology and Medicine* 82:532-535, March 1953.
52. The antimicrobial action of certain glycerol ethers and related compounds, (with C. V. Hubbard and B. J. Ludwig), *Applied Microbiology* 1:146-149, May 1953.
53. The convulsant and analeptic action of substituted 1, 3-diamino-2-propanols in mephenesin paralysis (with T. E. Lynes), *Journal of Pharmacology and Experimental Therapeutics* 109:407-412, December 1953.
54. The action of 1-(*o*-toloxy)-2,3-bis(2,2,2-trichloro-1-hydroxy-ethoxy)-propane (with T. E. Lynes), *Journal of Pharmacology and Experimental Therapeutics* 110:6, January 1954.
55. The effect of W181 (1-*n*-butylamino-3-*p*-toluidino-2-propanol) on the duration of paralysis or sleep produced by various central nervous system depressants (with T. E. Lynes), *Journal of Pharmacology and Experimental Therapeutics* 110:33-34, January 1954.
56. Combined action of barbiturates and mephenesin (with T. E. Lynes), *Federation Proceedings* 13:336, March 1954.
57. Hypnotic action resulting from combined administration of salicylamide and acetophenetidin, *Proceedings of the Society for Experimental Biology and Medicine* 87:449-451, November 1954.
58. The analeptic action of 1-*n*-butylamino-3-*p*-toluidino-2-propanol (W181) in sleep or paralysis produced by certain central nervous system depressants (with T. E. Lynes), *Journal of Pharmacology and Experimental Therapeutics* 112:399-403, December 1954.
59. The pharmacological properties of 2-methyl-2-*n*-propyl-1,3-propanediol dicarbamate (Miltown), a new interneuronal blocking agent, *Journal of Pharmacology and Experimental Therapeutics* 112:413-423, December 1954.

60. Effect of 2-methyl-2-n-propyl-1,3-propanediol dicarbamate (Miltown) on electrical activity of the brain (with C. D. Hendley and T. E. Lynes), *Proceedings of the Society for Experimental Biology and Medicine* 87:608-610, December 1954.
61. The effect of mephenesin on barbiturate anesthesia (with T. E. Lynes), *Archives Internationales de Pharmacodynamie et de Therapie* 100:401-408, January 1955.
62. Miltown, a long-acting mephenesin-like drug, *Federation Proceedings* 14:318-319, March 1955.
63. Effect of 2-methyl-2-n-propyl-1,3-propanediol dicarbamate (Miltown) on electrical activity of the brain (with C. D. Hendley and T. E. Lynes), *Federation Proceedings* 14:351, March 1955.
64. Central depressant and anticonvulsant activity of compounds isomeric with 2-methyl-2-n-propyl-1,3-propanediol dicarbamate (Miltown) (with C. D. Hendley, B. J. Ludwig and T. E. Lynes), *Journal of Pharmacology and Experimental Therapeutics* 116:337-342, March 1956.
65. Effect of meprobamate (Miltown) on animal behavior (motion picture) (with C. D. Hendley and T. E. Lynes), *Federation Proceedings* 15:436, March 1956.
66. Effects of meprobamate (Miltown), chlorpromazine and reserpine on behavior in the monkey (with C. D. Hendley and T. E. Lynes), *Federation Proceedings* 15:436-March 1956.
67. Meprobamate: its pharmacological properties and clinical uses. In "The New Chemotherapy of Mental Illness," edited by H. L. Gordon, Philosophical Library, New York, 1958, pp. 483-494. Reprint of article of same title from *International Record of Medicine and General Practice Clinics* 169:184-196, April 1956, with addendum.
68. Pharmacology of the psychotherapeutic drug benactyzine (beta-diethylaminoethyl benzilate hydrochloride) (with C. D. Hendley and T. E. Lynes), *Proceedings of the Society for Experimental Biology and Medicine* 92:563-566, July 1956.
69. Toxic effects of meprobamate, *British Medical Journal* ii:489, December 1956.

70. Effect of meprobamate on electrical activity of thalamus and other subcortical areas (with C. D. Hendley and T. E. Lynes). In "Tranquilizing Drugs," Publication No. 46 of the American Association for the Advancement of Science, Washington, D.C., 1957, pp.35-46.
71. The "new era" of psychiatry, Drug Trade News 32:60, January 28, 1957.
72. Some pharmacological properties of hydroxyzine (1-p-chlorobenzhydryl-4-(2-(2-hydroxyethoxy)-ethyl) diethyl-enediamine dihydrochloride) (with T. E. Lynes), Journal of Pharmacology and Experimental Therapeutics 119:163, February 1957.
73. The action of tranquilizers on brain potentials and serotonin (with G. L. Campbell, C. D. Hendley, B. J. Ludwig and T. E. Lynes), Annals of the New York Academy of Sciences 66(Art.3):686-694, March 1957.
74. The chemistry and mode of action of tranquilizing drugs, Annals of the New York Academy of Sciences 67 (Art. 10):685-699, May 1957.
75. Tranquilizing Drugs. In Britannica Book of the Year, 1958, Encyclopaedia Britannica, Inc., Chicago, p.689.
76. Central depressant properties of certain substituted glycols (with P. N. Cousins and C. C. Pattison), Journal of Pharmacology and Experimental Therapeutics 122:15A, January 1958.
77. The joint action of meprobamate and benactyzine (with C. C. Pattison and P. N. Cousins), Journal of Pharmacology and Experimental Therapeutics 122:60A, January 1958.
78. Tranquilizing Drugs. In Britannica Book of the Year, 1959, Encyclopaedia Britannica, Inc., Chicago, p.687.
79. Effect of meprobamate on limbic system of the brain (with M. Kletzkin). Proceedings of the Society for Experimental Biology and Medicine 100:681-683, April 1959.
80. Discussion of: H. Azima, J. Sangowicz, J. Spindler and F. J. Azima. Psychodynamic alterations concomitant with intensive meprobamate administration, Diseases of the Nervous System 20: Section 2 (monograph supplement), p.159, May 1959.
81. Review of Neomycin - Its Nature and Practical Application, edited by S. A. Waksman, et al. in American Scientist 47:298-146A, No. 2, June 1959.

82. Unusual muscle relaxant and analgesic properties of N-isopropyl-2-methyl-2-propyl-1,3-propanediol dicarbamate (carisoprodol) (with M. Kletzkin, B. J. Ludwig, S. Margolin and L. S. Powell), *Journal of Pharmacology and Experimental Therapeutics* 127:66-74, September 1959.
83. Effect of certain tranquilizers on the reticulo endothelial system (with R. Vinegar), *Proceedings of the Society for Experimental Biology and Medicine* 102:88-90, October 1959.
84. The muscle-relaxant and analgesic properties of carisoprodol. In "The Pharmacology and Clinical Usefulness of Carisoprodol," edited by J. G. Miller, Wayne State University Press, Detroit, Michigan, 1959, pp.25-37.
85. Tranquilizing Drugs. In *Britannica Book of the Year, 1960*, Encyclopaedia Britannica, Inc. Chicago, pp.687-688.
86. Neuropharmacology. Transactions of the Fifth Conference, May 27, 28 and 29, 1959, Princeton, N.J., sponsored by the Josiah Macy, Jr. Foundation, New York, N.Y., pp.90-95, 194-195.
87. Classification of psychoactive drugs according to their chemical structure and sites of action. In "Drugs and Behavior," edited by L. Uhr and J. G. Miller. John Wiley and Sons, Inc., New York, 1960, pp.86-105.
88. The purpose of this monograph. In "Non-narcotic Drugs for the Relief of Pain and Their Mechanism of Action," *Annals of the New York Academy of Sciences* 86:3-5, March 1960.
89. The history, chemistry and pharmacology of carisoprodol (with M. Kletzkin, B. J. Ludwig and S. Margolin). In "Non-narcotic Drugs for the Relief of Pain and Their Mechanism of Action," *Annals of the New York Academy of Sciences* 86:90-107, March 1960.
90. Religion, Science and Unitarianism, A sermon given at the Unitarian Church, Princeton, New Jersey on November 20, 1960.
91. Tranquilizers in psychiatry, *Lancet* 1:281, February 4, 1961.
92. A centrally acting blood pressure lowering agent (W-583), (with S. Margolin), *Federation Proceedings* 20:113, March 1961.
93. Studies on W-583 metabolism, (with J. F. Douglas, B. J. Ludwig and T. Ginsberg), *Federation Proceedings* 20:113, March 1961.
94. W-583, a centrally acting anti-pressor agent, (with M. Kletzkin), *Federation Proceedings* 20:113, March 1961.

95. The pharmacological properties of 2-methyl-2-sec-butyl-1, 3-propanediol dicarbamate (mebutamate, W-583), a new centrally acting blood pressure lowering agent, (with J. F. Douglas, M. Kletzkin, B. J. Ludwig and S. Margolin), *Journal of Pharmacology and Experimental Therapeutics* 134:356-365, December 1961.
- 95a. Structures of the major metabolites of meprobamate, (with B. J. Ludwig, J. F. Douglas, L. S. Powell and M. Meyer). *Journal of Medicinal and Pharmaceutical Chemistry* 3:53-64, No. 1, 1961.
96. Pharmacodynamics of meprobamate: differences between meprobamate and barbiturates. In "The First Hahnemann Symposium on Psychosomatic Medicine," edited by J. H. Nodine and J. G. Miller. Lea and Febiger, Philadelphia, 1962, pp.495-501.
97. Berger outlines theories of mental disease cause, *Drug Trade News*, 37:39 January 22, 1962.
98. Pharmacology of antihypertensive agents, *New York State Journal of Medicine* 62:1580-1585, May 15, 1962.
99. Evaluation of antidepressants, *New England Journal of Medicine* 267:839, October 18, 1962.
100. The treatment of anxiety, a critical review, *Journal of Neuropsychiatry* 2:98-103, December 1962.
101. Hazards of drugs in pregnancy, *British Medical Journal* 1:540, February 23, 1963.
102. The similarities and differences between meprobamate and barbiturates, *Clinical Pharmacology and Therapeutics* 4:209-233, March-April 1963.
103. Side-effects of meprobamate, *British Medical Journal* 2:936, October 12, 1963.
104. Effect of benzyl N-benzyl carbethoxyhydroxamate (W-398) on experimental atherosclerosis and hypercholesteremia, (with J. F. Douglas, B. J. Ludwig and S. Margolin), *Proceedings of the Society for Experimental Biology and Medicine* 114:337-341, November 1963.
105. Endotoxin induced resistance to infections and tolerance, (with G. Fukui,) *Proceedings of the Society for Experimental Biology and Medicine* 114:780-783, December 1963.

106. Distribution, absorption and metabolic fate of tybamate, (with J. F. Douglas, J. Edelson, A. Schlosser and B. J. Ludwig), Federation Proceedings 23:489, March-April 1964.
107. The future of tranquilizers, American Professional Pharmacist 30:50-52, May 1964.
108. Pharmacologic properties of a new tranquillizing agent, 2-methyl-2-propyltrimethylene butylcarbamate carbamate (tybamate), (with M. Kletzkin and S. Margolin), Medicina Experimentalis (Basel) 10:327-344, 1964.
109. The tranquilizer decade, Journal of Neuropsychiatry 5:403-410, October 1964.
110. Meprobamate and related compounds (with B. J. Ludwig). In "Psychopharmacological Agents," Volume 1, edited by M. Gordon. Academic Press, New York, 1964, pp.103-135.
111. Effects of combined benactyzine-meprobamate administration upon the limbic system and EEG, (with M. Kletzkin), Federation Proceedings 24:391, March-April 1965.
112. Anxiety and its treatment, Journal of the American Society of Psychosomatic Dentistry and Medicine 12:53-64, July 1965.
113. The combined action of meprobamate and benactyzine, (with M. Ketzkin and S. Margolin), Medicina et Pharmacologia Experimentalis 13:103-116, 1965.
114. Failure of chronic tybamate intoxication to induce withdrawal convulsions in dogs, (with S. Margolin and O. J. Plekss), Pharmacologist 7:143, Fall 1965.
115. Major and minor tranquilizers, Journal of the American Medical Association 194:681-682, November 8, 1965.
116. Why we should use drugs in managing the anxious patient. In "Controversy in Internal Medicine," edited by F. J. Ingelfinger, A. S. Relman and M. Finland. Saunders, Philadelphia, 1966, pp.625-632.
117. Studies on the mechanism of the hypocholesterolemic action of benzyl N-benzyl carbethoxyhydroxamate (W-398), (with J. F. Douglas, B. J. Ludwig and S. Margolin), Journal of Atherosclerosis Research 6:90-97, January-February 1966.

118. Role of drugs in suicide, *Current Medical Digest* 33:250-251, 255, February 1966.
119. Control of the mind, *American Journal of Pharmacy* 138:51-56, March-April 1966.
120. Evaluation of tranquilizers. The techniques and their meaning. In "Methods in Drug Evaluation," Proceedings of the International Symposium (Milano, 1965), edited by P. Mantegazza and F. Piccinini. North-Holland Publishing Company, Amsterdam, 1966, pp.218-233.
121. Selective suppression of penicillin hypersensitivity by certain phenoxy propanediols, (with G. Fukui, B. J. Ludwig and S. Margolin), Proceedings of the Society for Experimental Biology and Medicine 124:303-310, January 1967.
122. Control of the mind, *American Scientist* 55:67-71, March 1967.
123. Drugs and suicide in the United States, *Clinical Pharmacology and Therapeutics* 8:219-223, March-April 1967.
124. Two types of PCA evoking penicillin antibodies, (with G. M. Fukui, L. May, E. G. Goldenbaum and M. DeAngelo), *Bacteriological Proceedings*, 1967, p.66.
125. The action of certain tranquilizers, antidepressants and anticholinergic drugs on hippocampal afterdischarges, (with M. Kletzkina and S. Margolin). In "Anti-Depressant Drugs," Proceedings of the First International Symposium (Milan, 1966), edited by S. Garattini and M.N.G. Dukes. Excerpta Medica, New York 1967, pp.241-246.
126. The synthesis of hydroxylamine derivatives possessing hypocholesteremic activity, (with B. J. Ludwig, F. Dursch, M. Auerbach and K. Tomeczek), *Journal of Medicinal Chemistry* 10:556-564, July 1967.
127. The physicians' counselor...A tribute to Harry Beckman, *Wisconsin Medical Journal* 66:312-313, July 1967.
128. Influence of benzyl N-benzyl carbethoxyhydroxamate, W-398, on tissue lipids of rats and rabbits, (with J. F. Douglas, B. J. Ludwig and S. Margolin). In "Progress in Biochemical Pharmacology," Volume 2, Second International Symposium on Drugs Affecting Lipid Metabolism (Milan, 1965), edited by D. Kritchevsky, R. Paoletti and D. Steinberg. Karger, New York, 1967, pp. 422-431.

129. The antidepressant action of certain tranquilizers and its reinforcement by anticholinergic drugs, (with M. Kletzkin and S. Margolin). In "Neuro-Psycho-Pharmacology," edited by H. Brill. Excerpta Medica Foundation (New York, 1966), pp.1055-1060, 1967.
130. The effect of endotoxin on resistance to infection and disease. In "Advances in Pharmacology," Volume 5, edited by S. Garattini and P. A. Shore. Academic Press, New York, 1967, pp.19-46.
131. The role of drugs in suicide. In "Symposium on Suicide," edited by L. Yochelson. George Washington University, Washington, D.C., 1967, pp.117-132.
132. Pharmacology of anti-anxiety tranquilizers, *Chimica Therapeutica* 2:166, May-June 1967.
133. Computers and medical discoveries, *Perspectives in Biology and Medicine* 11:63-70, Autumn 1967.
134. Suppression of penicillin induced passive cutaneous anaphylaxis reaction with phenoxypropanediols, (with G. M. Fukui), *Giornale Dell' Arteriosclerosi* 5:551-563, September-October 1967.
135. Increase of nonspecific resistance to infection by protodyne, a protein component derived from bacterial protoplasm, (with G. M. Fukui, B. J. Ludwig and J. P. Rosselet), *Proceedings of the Society for Experimental Biology and Medicine* 127:556-559, February 1968.
136. Protodyne: a proteinaceous host resistance increasing substance of bacterial origin, (with G. M. Fukui, B. J. Ludwig and J. P. Rosselet), *Federation Proceedings* 27:538, March-April 1968.
137. Penicillin-proteins in antibody synthesis and chlorphenesin suppression by plaque assay, (with G. Chandlee, S. Czaplicki and (with G. Fukui), *Bacteriological Proceedings*, 1968, p.66.
138. Effect of plasma on non-specific resistance to infection induced by endotoxin or protodyne, (with G. M. Fukui and E. Goldenbaum), *Nature (London)* 218:362-363, April 27, 1968.
139. Book review of *The Medical Messiahs*, edited by J. H. Young in *American Scientist* 56:156A-157A, Summer 1968.

140. The effect of N-gamma-phenylpropyl-N-benzyloxy acetamide (W-1372) on tissue lipids, (with B. J. Ludwig, J. F. Douglas and S. Margolin). Proceedings of the Third International Symposium on Drugs Affecting Lipid Metabolism, Milan, Italy, September 9-11, 1968. (An Abstract).
141. Effect of chlorphenesin on localized hemolysis in gel assay, (with G. M. Fukui, G. C. Chandlee and E. G. Goldenbaum), *Journal of Bacteriology* 96:1133-1136, October 1968.
142. The relation between the pharmacological properties of meprobamate and the clinical usefulness of the drug. In "Psychopharmacology (A Review of Progress 1957-1967)," edited by D. H. Efron. Superintendent of Documents, Washington, D.C., 1968, pp.139-152.
143. The significance of laboratory studies in the evaluation and discovery of psychoactive agents in man. *Diseases of the Nervous System* 30(Supplement):5-10, February 1969.
144. The effect of W-1372 and clofibrate on serum cholesterol of normal and hypercholesteremic rats, (with G. G. Lu), *Federation Proceedings* 28:677, March-April 1969.
145. The effect of chlorphenesin on the immune response, (with G. M. Fukui, E. G. Goldenbaum, M. DeAngelo and G. C. Chandlee), *Journal of Immunology* 102:1024-1031, April 1969.
146. Carbamate derivatives related to meprobamate, (with B. J. Ludwig and L. S. Powell), *Journal of Medicinal Chemistry* 12:462-472, May 1969.
147. A non-lipopolysaccharide host resistance-increasing substance isolated from the protoplasm of gram negative bacteria, (with G. M. Fukui, B. J. Ludwig and J. P. Rosselet), *Colloques Internationaux du Centre National de la Recherche Scientifique* 174:285-295, 1969.
148. The effect of antianxiety tranquilizers on the behavior of normal persons, (with J. Potterfield). In "The Psychopharmacology of the Normal Human," edited by W. O. Evans and N. S. Kline. C. C. Thomas, Springfield, Illinois, 1969, pp. 38-113.
149. Increased host resistance to infection elicited by lipopolysaccharides from *Brucella abortus*, (with G. M. Fukui, B. J. Ludwig and J. P. Rosselet), *Proceedings of the Society for Experimental Biology and Medicine* 131:1376-1381, September 1969.

150. Effect of N-gamma-phenylpropyl-N-benzyloxy acetamide (W-1372) and clofibrate on the lipids of normal and hypercholesteremic rats, (with J. F. Douglas, G. G. Lu and B. J. Ludwig), *Proceedings of the Society for Experimental Biology and Medicine* 132:293-297, October 1969.
151. Mental disease and drugs affecting it, *Perspectives in Biology and Medicine* 13:31-44, Autumn 1969.
152. The effect of N-gamma-phenylpropyl-N-benzyloxy acetamide (W-1372) on experimental atherosclerosis and hypercholesteremia, (with J. F. Douglas, B. J. Ludwig and S. Margolin), *Journal of Pharmacology and Experimental Therapeutics* 170:371-381, December 1969.
153. Drug abuse and society, (with J. Potterfield). In "Drugs and Youth," edited by J. R. Wittenborn, H. Brill, J. P. Smith and S. A. Wittenborn. C. C. Thomas, Springfield, Illinois, 1969, pp.37-43.
154. Remarks. In "Drug Information for the Health Professions," edited by I. D. Welt. Gordon and Breach, New York, 1969, pp. 20 passim.
155. The effect of N-gamma-phenylpropyl-N-benzyloxy acetamide (W-1372) and clofibrate on lipid deposits induced in rats by a high fat diet, (with J. F. Douglas, G. G. Lu and B. J. Ludwig), *Federation Proceedings* 29:385, March-April 1970.
156. Introduction. In "Principles of Psychopharmacology," edited by W. G. Clark and J. del Giudice, Academic Press, New York, 1970, pp.3-8.
157. The increase of non-specific resistance to bacterial infections by extracts obtained from *Brucella abortus*, (with G. M. Fukui, B. J. Ludwig and J. P. Rosselet). In "International Symposium on Brucellosis," Symposia Series in Immunobiological Standardization, Volume 12, (Tunis, 1968), edited by R. H. Regamey, A. de Barbieri, W. Hennesen, D. Ilic and F. T. Perkins. Karger, New York, 1970, pp.269-280.
158. Anxiety and the discovery of the tranquilizers. In "Discoveries in Biological Psychiatry," edited by F. J. Ayd, Jr. and B. Blackwell. J. B. Lippincott Company, Philadelphia, 1970, pp.115-129.
159. Antibiotic and hypersensitivity studies of N6-(P-chlorophenoxy lactyl)-6-amino penicillanic acid, (with G. M. Fukui, B. J. Ludwig and C. V. Hubbard). In "Progress in Antimicrobial and Anticancer Chemotherapy," *Proceedings of the Sixth International Congress of Chemotherapy*, University of Tokyo Press, Tokyo, Volume 1, 1970, pp.557-561.

160. Potential anti-inflammatory agents. Aralkoxyhydrouracils and aralkoxyhydantoins, (with L. Simet, D. B. Reisner, B. J. Ludwig and F. Dursch), *Journal of Medicinal Chemistry* 13:1067-1071, November 1970.
161. A proteinaceous host resistance increasing substance derived from the protoplasm of gram-negative bacteria, (with G. M. Fukui, B. J. Ludwig and J. P. Rosselet). In "International Symposium on Enterobacterial Vaccines," Symposia Series in Immunobiological Standardization, Volume 15, (Berne, 1969), edited by R. H. Regamey, M. Stanic and J. Ungar. Karger, New York, 1971, pp.15-28.
162. Influence of meprobamate on the fetus, fertility and postnatal development, (with M. Kletzkin). In "Malformations Congenitales des Mammiferes," edited by H. Tuchmann-Duplessis. Masson, Paris, 1971, pp.255-272.
163. Studies on the mechanism of protodyne-induced protection against microbial infections, (with G. M. Fukui, R. H. Gustafson and J. P. Rosselet), *Proceedings of the Society for Experimental Biology and Medicine* 138:391-395, November 1971.
164. The drugs of the future. In "Abstracts of the Fifth World Congress of Psychiatry, Mexico City (November 28-December 4) 1971, pp.106-107.
165. Biological study of a nontoxic water-soluble immunoadjuvant from mycobacterial cell walls (with L. Chedid, M. Parant, F. Parant and R. H. Gustafson), *Proc.Nat.Acad.Sci.U.S.A.* 69:855-858, April 1972.
166. The pharmacological properties of 7-chloro-3,3a-dihydro-2H, 9H - isoxazolo (3,2-b) (1,3) benzoxazin-9-one, W2354, a new anti-inflammatory agent (with M. Kletzkin and H. J. Spencer), *Federation Proceedings* 31:578, April 1972.
167. Attenuation of certain neoplasias by chlorphenesin, (with H. J. Spencer, R. H. Runser, G. S. Tarnowski and G. Mathe), *Proceedings of the Society for Experimental Biology and Medicine* 140:1156-1161, September 1972.
168. Social implication of psychotropic drugs. *Advances in Pharmacology and Chemotherapy* 10:105-118, 1972.
169. The pharmacological properties of Seclazone (7-chloro-3,3a-dihydro-2H, 9H-isoxazolo (3,2-b) (1,3) benzoxazin-9-one, a new anti-inflammatory agent, (with H. M. Bates, W. Diamantis, K. Kletzkin, O. J. Plekss, R. D. Sofia and H. J. Spencer), *Pharmacology* 9:164-176, March 1973).

170. Antihypertensive action of 5-(dimethylaminoacetyl)-1.2.3.4.4a.5.6.11a-octahydromorphanthridine hydrochloride (W-2587), (with J. F. Schaefer, Jr., R. R. Loetzer, G. B. Phillips, B. J. Ludwig and M. Kletzkin), Federation Proceedings 32:750, March 1973.
171. Anti-inflammatory, analgesic and antipyretic activities of W-2395, 7-chloro-3,3a-dihydro-2-methyl-2H, 9H-isoxazolo (3,2-b) (1,3)-benzoxazin-9-one, (with R. D. Sofia, W. Diamantis and M. Kletzkin), Federation Proceedings 32:751, March 1973.
172. Preparation and biological properties of water soluble adjuvant fractions from delipidated cells of *Mycobacterium smegmatis* and *Nocardia opaca*, (with A. Adam, R. Ciorbaru, J. F. Petit, E. Lederer, L. Chedid, A. Lamensans, F. Parant, M. Parant and J. P. Rosselet), Infection and Immunity 7:855-861, June 1973.
173. The drugs of the future. In "Proceedings of the V World Congress of Psychiatry, Mexico, D. F., 25 November-4 December 1971," edited by Fuente, Ramon de la and Weissman, Maxwell N., New York and Amsterdam, Excerpta Medica International Congress Series No. 274, 1973, pp.588-593.
174. Pharmacology of a new non-steroidal anti-inflammatory agent 7-chloro-3, 3a-dihydro-2-methyl-2H, 9H-isoxazolo (3,2-b) (1,3) benzoxazin-9-one (W-2395), (with R. D. Sofia, W. Diamantis, R. Gordon, M. Kletzkin, J. Edelson, H. Singer and J. F. Douglas), European Journal of Pharmacology 26:51-62, April 1974.
175. The pharmacology of antianxiety (anxiolytic) agents. In "Psychopharmacological Treatment, Theory and Practice," edited by Herman C. B. Denber. Marcel Dekker, Inc., New York, 1975, pp.135-156.
176. Depression and antidepressant drugs. Clinical Pharmacology and Therapeutics, 18:241-248, September 1975.
177. Enhancement of immunity against murine syngeneic tumors by a fraction extracted from non-pathogenic mycobacteria (with A. Lemensans, L. Chedid, E. Lederer, J. P. Rosselet, R. H. Gustafson, H. J. Spencer and B. J. Ludwig), Proceedings of the National Academy of Science, U.S.A. 72:3656-3660, September 1975.
178. Present status of clinical psychopharmacology. Clinical Pharmacology and Therapeutics, 19:725-731, June 1976.

179. Therapeutic uses of meprobamate and the propanediols. In "Drug Treatment of Mental Disorders," edited by L. L. Simpson, Raven Press, New York, pp.91-107, 1976.
180. Aminergic factors in mental illness. In "Current Developments in Psychopharmacology," 3:127-153, Spectrum Publications, Inc., New York, 1976.
181. Benzodiazepine enhancement of propoxyphene analgesia, (with M. E. Ellis and H. L. Johnson), Federation Proceedings, 36:1024, March 1977.
182. Meprobamate and other glycol derivatives. In "Psychotherapeutic Drugs," Vol. 2, edited by E. Usdin and I. S. Forrest. Marcel Dekker, Inc., New York, pp.1089-1100, 1977.
183. Awareness groups and psychiatric. Biosciences Communications, 3:89-98, No. 2, 1977.
184. Ernest Singer, Obituary. The Medical Journal of Australia, 1:863, June 1977.
185. Za Arnostem Singerem (Ernest Singer, obituary), Casopis lekaru ceskych, 116:1318, October 1977.
186. The encounter and awareness movements and health care delivery. In "The American Biomedical Network," S. B. Day, R. V. Cuddihy and H. H. Fudenberg, editors. Scripta Medica & Technica, South Orange, N.J., pp.87-89, 1977.
187. The analgesic action of combinations of propoxyphene and benzodiazepines, (with J. M. Dille and H. L. Johnson), The International Congress of Pharmacology, IUPHAP, Abstract number 536, Pergamon Press, Paris, July 1978, p.204.
188. Introduction: The aims and achievements of psychopharmacology. In "Principles of Psychopharmacology," edited by W. G. Clark and J. del Guidice. 2nd edition. Academic Press, New York, 1979, pp.1-7.
189. Anxiety. In "A companion to the life sciences," Vol. 1., edited by Stacey B. Day. Van Nostrand Reinhold Company, New York, 1979, p.66.
190. Effects of chlorphenesin on immune reactions in vivo and in vitro, (with Jana Raskova), Federation Proceedings 38:1366, (Abstract 6013), March 1979.

191. 4-(p-Chlorophenylthio)-butanol (W-2719), a new non-antihistaminic drug for immediate hypersensitivity allergies, (with G. M. Fukui, B. J. Ludwig, R. D. Sofia and D. B. Reisner), *Arzneimittel Forschung-Drug Research* 29(1):912-917, June 1979.
192. Suppressive effects of chlorphenesin on lymphocyte function in mice and humans, (with D. P. Stites, G. Brecher and L. Schmidt), *Immunopharmacology* 2:39-49, 1979.
193. Effect of antianxiety drugs on fear and stress. *Behavioral Sciences* 25:315-321, July 1980.
194. The use of antianxiety drugs. Commentary. *Clinical Pharmacology and Therapeutics* 29:291-294, March 1981.
195. How to be happy in spite of life's vicissitudes. In "Life Stress," Volume III of Companion to the Life Sciences, Stacey B. Day, editor. Van Nostrand Reinhold Company, New York, pp.104-109, 1982.
196. Carbammati, Farmacologia in "Enciclopedia della Chimica," Volume II, USES Edizioni Scientifiche, Firenze 1972. pp.700-702.
197. James Madison Dille, Obituary. *The Pharmacologist* 30:31-32. 1988.
198. The "Social Chemistry" of Pharmacological Discovery: The Milltown Story. *Social Pharmacology* 2:(3):189-204. 1988.
199. Protodyne: An immunomodulatory protein component, prepared from *Bacillus subtilis* (with V. Houba as first author, J. Le, J. Mauel, J. Vilcek, M. T. E. Vogels and F. M. Berger). 4th Interscience World Conference on Inflammation, Antirheumatics, Analgesics, Immunomodulators. Palexpo, Geneva, Switzerland. April 15-18, 1991. Abstract 162.
200. Protodyne: An immunomodulatory protein component, prepared from gram-positive *Bacillus subtilis* (with V. Houba as first author, J. Le, W. M. Van der Meer, J. Vilcek and F. M. Berger). Symposium on standardization of the immunopharmacology of natural and synthetic immunomodulators arranged by the International Association of Biological Standardization at Annecy, France, May 15-17, 1991. Abstract 40-O, p.68.
201. Protodyne: An immunomodulatory protein component, prepared from *Bacillus subtilis* (with V. Houba as first author, and F. M. Berger, C. A. Dinarello, A. G. Johnson, J. Le, J. Mauel, J. W. M. Van Der Meer, M. M. Philippeaux, J. Vilcek, M. T. E. Vogels). *International Journal of Immunotherapy* VIII (3):109-116, 1991.

202. Irving H. Page. Obituary. *The Pharmacologist* 34(1):34-35. 1992.
203. Protodyne: An immunostimulatory protein component, prepared from gram-positive *Bacillus subtilis* (with V. Houba as first author, and F. M. Berger, C. A. Dinarello, A. G. Johnson, J. Le, J. Mauel, J. W. M. Van Der Meer, M. M. Philippeaux, J. Vilcek, M. T. E. Vogels). *Develop. Biol. Standard.*, 77:121-128, Karger, Basel, 1992.
204. Lob der Tranquilizer (In Praise of Tranquilizers) in "Angsterkrankungen, Prevention und Therapie" (Anxiety disorders, prevention and therapy), Gerhard Nissen, editor, Verlag Hans Huber, Bern pp.77-79, 1995.
205. Introduction of Antianxiety Drugs. In "Towards CINP," T. A. Ban and H. Hippus, editors. J. M. Productions, Brentwood, Tennessee, pp.24-26, June 1994. Also in "A History of the CINP," T. A. Ban and O. S. Ray, editors. J. M. Productions, Brentwood, Tennessee, pp.281-283, 1996.
206. Propanediols. Half a Century of Tranquilizer Use. In "A History of the CINP," T. A. Ban and O. S. Ray, editors. J. M. Productions, Brentwood, Tennessee, pp.418-421, 1996.
207. As I Remember, in "The Rise of Psychopharmacology And The Story Of CINP," T. A. Ban, D. Healy and E. Shorter, editors. Animula Publishing House, Budapest, pp. 59-62, 1998.

SCIENTIFIC PUBLICATIONS

BY SUBJECT CATEGORIES

Frank M. Berger, M.D.

Mephenesin and Other Muscle Relaxants	p. 1
Meprobamate and Related Drugs	p. 3
Atherosclerosis	p. 7
Anti-inflammatory Drugs	p. 8
Pharmacology	p. 9
Biological Response Modifiers and Immunoadjuvants	p. 12
Microbiology and Immunology	p. 15
Penicillin	p. 16
Psychiatry	p. 17
Reviews and Miscellaneous Writings	p. 19

MEPHENESIN AND OTHER MUSCLE RELAXANTS

16. The pharmacological properties of alpha, beta-dihydroxy-gamma-(2-methylphenoxy)-propane (myanesin) (with W. Bradley), *British Journal of Pharmacology and Chemotherapy* 1:265-272, December 1946.
18. The muscle-relaxing action of myanesin (with W. Bradley), *Lancet* 1:97, January 18, 1947.
19. The effect of analeptic and other substances on the paralyzing action of myanesin, *Quarterly Journal of Pharmacy and Pharmacology* 20:94-99, April-June 1947.
20. Muscle-relaxing ethers of glycerol (with W. Bradley), *Nature (London)* 159:813-814, June 14, 1947.
21. The mode of action of myanesin, *British Journal of Pharmacology and Chemotherapy* 2:241-250, December 1947.
22. For and against myanesin, *Lancet* 1:651, April 24, 1948.
23. Oral myanesin in the treatment of spastic and hyperkinetic disorders (with R. P. Schwartz), *Journal of the American Medical Association* 137:772-774, June 26, 1948.
24. The toxicity and muscular effect of d-tubocurarine combined with beta-erythroidine, myanesin or evipal (with R. P. Schwartz), *Journal of Pharmacology and Experimental Therapeutics* 93:362-367, July 1948.
25. The relationship between chemical structure and central depressant action of substituted ethers of glycerol, *Journal of Pharmacology and Experimental Therapeutics* 93:470-481, August 1948.
26. The pharmacological properties of some 2-substituted-4-hydroxy-methyl-1,3-dioxolanes (with V. Boekelheide and D. S. Tarbell), *Science* 108:561-562, November 19, 1948.
27. Metabolism of myanesin (3-(*o*-toloxy)-1,2-propanediol) (with R. F. Riley), *Archives of Biochemistry* 20:159-160, January 1949.

28. Paralyzing action of 2-methyl,2-n-amyl-hydroxy-methyl-1,3-dioxolane (glyketal), Federation Proceedings 8:274, March 1949.
29. Preparation and pharmacological properties of the acid succinate of myanesin (with R.F. Riley), Federation Proceedings 8:328, March 1949.
30. Anticonvulsant action of 2-substituted-1,3-propanediols, Proceedings of the Society for Experimental Biology and Medicine 71:270-271, June 1949.
32. The pharmacological properties of 2-methyl, 2-n-amyl-4-hydroxy-methyl-1, 3-dioxolane (glyketal), a new blocking agent of interneurons, Journal of Pharmacology and Experimental Therapeutics 96:213-223, July 1949.
33. The preparation and pharmacological properties of the acid succinate of 3-(*o*-toloxy)-1,2-propanediol (myanesin) (with R. F. Riley), Journal of Pharmacology and Experimental Therapeutics 96:269-275, July 1949.
36. Haemolytic effects of myanesin, Lancet 1:90, January 14, 1950.
39. Paralyzing and anticonvulsant properties of substituted n-propyl-*o*-tolyl ethers (with B. J. Ludwig), Journal of Pharmacology and Experimental Therapeutics 101:2, January 1951.
40. The paralyzing activity of some substituted dioxolanes in relation to their structure, Archives Internationales de Pharmacodynamie et de Therapie 85:474-483, February 1951.
47. Central depressant and anticonvulsant properties of glycerol ethers isomeric with mephenesin, Journal of Pharmacology and Experimental Therapeutics 105:450-457, August 1952.
49. The analeptic action of 1-*n*-butylamino-3-*p*-toluidino-2-propanol (W181) in mephenesin paralysis, Journal of Pharmacology and Experimental Therapeutics 107:250-257, February 1953.
50. The action of mephenesin on body temperature (with T. E. Lynes), Federation Proceedings 12:345, March 1953.
51. Hemolytic action of water soluble compounds related to mephenesin (with C. V. Hubbard and B. J. Ludwig), Proceedings of the Society for Experimental Biology and Medicine 82:532-535, March 1953.

53. The convulsant and analeptic action of substituted 1, 3-diamino-2-propanols in mephenesin paralysis (with T. E. Lynes), *Journal of Pharmacology and Experimental Therapeutics* 109:407-412, December 1953.
54. The action of 1-(o-toloxo)-2,3-bis(2,2,2-trichloro-1-hydroxy-ethoxy)-propane (with T. E. Lynes), *Journal of Pharmacology and Experimental Therapeutics* 110:6, January 1954.
56. Combined action of barbiturates and mephenesin (with T. E. Lynes), *Federation Proceedings* 13:336, March 1954.
61. The effect of mephenesin on barbiturate anesthesia (with T. E. Lynes), *Archives Internationales de Pharmacodynamie et de Therapie* 100:401-408, January 1955.

MEPROBAMATE AND RELATED DRUGS

37. Pharmacological properties of 2,2-diethyl-1,3-propanediol (DEP) (with B. J. Ludwig and C. Russo), *Federation Proceedings* 9:258, March 1950.
38. The anticonvulsant action of 2,2-diethyl-1,3-propanediol (DEP) and some of its homologues and esters (with B. J. Ludwig), *Journal of Pharmacology and Experimental Therapeutics* 100:27-37, September 1950.
41. Anticonvulsant activity 2,2-disubstituted-1,3-propanediols in electroshock seizures, *Proceedings of the Society for Experimental Biology and Medicine* 78:277-279, October 1951.
44. The anticonvulsant activity of carbamate esters of certain 2,2-disubstituted-1,3-propanediols, *Journal of Pharmacology and Experimental Therapeutics* 104:229-233, February 1952.
46. The central depressant properties of *o*-toloxypropyl carbamates, *Journal of Pharmacology and Experimental Therapeutics* 104:468-473, April 1952.

59. The pharmacological properties of 2-methyl-2-*n*-propyl-1,3-propanediol dicarbamate (Miltown), a new interneuronal blocking agent, *Journal of Pharmacology and Experimental Therapeutics* 112:413-423, December 1954.
60. Effect of 2-methyl-2-*n*-propyl-1,3-propanediol dicarbamate (Miltown) on electrical activity of the brain (with C. D. Hendley and T. E. Lynes), *Proceedings of the Society for Experimental Biology and Medicine* 87:608-610, December 1954.
62. Miltown, a long-acting mephenesin-like drug, *Federation Proceedings* 14:318-319, March 1955.
63. Effect of 2-methyl-2-*n*-propyl-1,3-propanediol dicarbamate (Miltown) on electrical activity of the brain (with C. D. Hendley and T. E. Lynes), *Federation Proceedings* 14:351, March 1955.
64. Central depressant and anticonvulsant activity of compounds isomeric with 2-methyl-2-*n*-propyl-1,3-propanediol dicarbamate (Miltown) (with C. D. Hendley, B. J. Ludwig and T. E. Lynes), *Journal of Pharmacology and Experimental Therapeutics* 116:337-342, March 1956.
65. Effect of meprobamate (Miltown) on animal behavior (motion picture) (with C. D. Hendley and T. E. Lynes), *Federation Proceedings* 15:436, March 1956.
66. Effects of meprobamate (Miltown), chlorpromazine and reserpine on behavior in the monkey (with C. D. Hendley and T. E. Lynes), *Federation Proceedings* 15:436-March 1956.
67. Meprobamate: its pharmacological properties and clinical uses. In "The New Chemotherapy of Mental Illness," edited by H. L. Gordon, Philosophical Library, New York, 1958, pp. 483-494. Reprint of article of same title from *International Record of Medicine and General Practice Clinics* 169:184-196, April 1956, with addendum.
69. Toxic effects of meprobamate, *British Medical Journal* ii:489, December 1956.
70. Effect of meprobamate on electrical activity of thalamus and other subcortical areas (with C. D. Hendley and T. E. Lynes). In "Tranquilizing Drugs," Publication No. 46 of the American Association for the Advancement of Science, Washington, D.C., 1957, pp.35-46.

76. Central depressant properties of certain substituted glycols (with P. N. Cousins and C. C. Pattison), *Journal of Pharmacology and Experimental Therapeutics* 122:15A, January 1958.
77. The joint action of meprobamate and benactyzine (with C. C. Pattison and P. N. Cousins), *Journal of Pharmacology and Experimental Therapeutics* 122:60A, January 1958.
79. Effect of meprobamate on limbic system of the brain (with M. Kletzkin). *Proceedings of the Society for Experimental Biology and Medicine* 100:681-683, April 1959.
80. Discussion of: H. Azima, J. Sangowicz, J. Spindler and F. J. Azima. Psychodynamic alterations concomitant with intensive meprobamate administration, *Diseases of the Nervous System* 20: Section 2 (monograph supplement), p.159, May 1959.
82. Unusual muscle relaxant and analgesic properties of N-isopropyl-2-methyl-2-propyl-1,3-propanediol dicarbamate (carisoprodol) (with M. Kletzkin, B. J. Ludwig, S. Margolin and L. S. Powell), *Journal of Pharmacology and Experimental Therapeutics* 127:66-74, September 1959.
84. The muscle-relaxant and analgesic properties of carisoprodol. In "The Pharmacology and Clinical Usefulness of Carisoprodol," edited by J. G. Miller, Wayne State University Press, Detroit, Michigan, 1959, pp.25-37.
89. The history, chemistry and pharmacology of carisoprodol (with M. Kletzkin, B. J. Ludwig and S. Margolin). In "Non-narcotic Drugs for the Relief of Pain and Their Mechanism of Action," *Annals of the New York Academy of Sciences* 86:90-107, March 1960.
91. Tranquilizers in psychiatry, *Lancet* 1:281, February 4, 1961.
92. A centrally acting blood pressure lowering agent (W-583), (with S. Margolin), *Federation Proceedings* 20:113, March 1961.
93. Studies on W-583 metabolism, (with J. F. Douglas, B. J. Ludwig and T. Ginsberg), *Federation Proceedings* 20:113, March 1961.
94. W-583, a centrally acting anti-pressor agent, (with M. Kletzkin), *Federation Proceedings* 20:113, March 1961.

95. The pharmacological properties of 2-methyl-2-sec-butyl-1, 3-propanediol dicarbamate (mebutamate, W-583), a new centrally acting blood pressure lowering agent, (with J. F. Douglas, M. Kletzkin, B. J. Ludwig and S. Margolin), *Journal of Pharmacology and Experimental Therapeutics* 134:356-365, December 1961.
- 95a. Structures of the major metabolites of meprobamate, (with B. J. Ludwig, J. F. Douglas, L. S. Powell and M. Meyer). *Journal of Medicinal and Pharmaceutical Chemistry* 3:53-64, No. 1, 1961.
96. Pharmacodynamics of meprobamate: differences between meprobamate and barbiturates. In "The First Hahnemann Symposium on Psychosomatic Medicine," edited by J. H. Nodine and J. G. Miller. Lea and Febiger, Philadelphia, 1962, pp.495-501.
102. The similarities and differences between meprobamate and barbiturates, *Clinical Pharmacology and Therapeutics* 4:209-233, March-April 1963.
103. Side-effects of meprobamate, *British Medical Journal* 2:936, October 12, 1963.
106. Distribution, absorption and metabolic fate of tybamate, (with J. F. Douglas, J. Edelson, A. Schlosser and B. J. Ludwig), *Federation Proceedings* 23:489, March-April 1964.
108. Pharmacologic properties of a new tranquillizing agent, 2-methyl-2-propyltrimethylene butylcarbamate carbamate (tybamate), (with M. Kletzkin and S. Margolin), *Medicina Experimentalis (Basel)* 10:327-344, 1964.
110. Meprobamate and related compounds (with B. J. Ludwig). In "Psychopharmacological Agents," Volume 1, edited by M. Gordon. Academic Press, New York, 1964, pp.103-135.
111. Effects of combined benactyzine-meprobamate administration upon the limbic system and EEG, (with M. Kletzkin), *Federation Proceedings* 24:391, March-April 1965.
113. The combined action of meprobamate and benactyzine, (with M. Ketzkin and S. Margolin), *Medicina et Pharmacologia Experimentalis* 13:103-116, 1965.

114. Failure of chronic tybamate intoxication to induce withdrawal convulsions in dogs, (with S. Margolin and O. J. Plekss), *Pharmacologist* 7:143, Fall 1965.
142. The relation between the pharmacological properties of meprobamate and the clinical usefulness of the drug. In "Psychopharmacology (A Review of Progress 1957-1967)," edited by D. H. Efron. Superintendent of Documents, Washington, D.C., 1968, pp.139-152.
162. Influence of meprobamate on the fetus, fertility and postnatal development, (with M. Kletzkin). In "Malformations Congenitales des Mammiferes," edited by H. Tuchmann-Duplessis. Masson, Paris, 1971, pp.255-272.

ATHEROSCLEROSIS

104. Effect of benzyl N-benzyl carbethoxyhydroxamate (W-398) on experimental atherosclerosis and hypercholesteremia, (with J. F. Douglas, B. J. Ludwig and S. Margolin), *Proceedings of the Society for Experimental Biology and Medicine* 114:337-341, November 1963.
126. The synthesis of hydroxylamine derivatives possessing hypocholesteremic activity, (with B. J. Ludwig, F. Dursch, M. Auerbach and K. Tomeczek), *Journal of Medicinal Chemistry* 10:556-564, July 1967.
128. Influence of benzyl N-benzyl carbethoxyhydroxamate, W-398, on tissue lipids of rats and rabbits, (with J. F. Douglas, B. J. Ludwig and S. Margolin). In "Progress in Biochemical Pharmacology," Volume 2, Second International Symposium on Drugs Affecting Lipid Metabolism (Milan, 1965), edited by D. Kritchevsky, R. Paoletti and D. Steinberg. Karger, New York, 1967, pp. 422-431.
140. The effect of N-gamma-phenylpropyl-N-benzyloxyacetamide (W-1372) on tissue lipids, (with B. J. Ludwig, J. F. Douglas and S. Margolin). *Proceedings of the Third International Symposium on Drugs Affecting Lipid Metabolism, Milan, Italy, September 9-11, 1968. (An Abstract).*
144. The effect of W-1372 and clofibrate on serum cholesterol of normal and hypercholesteremic rats, (with G. G. Lu), *Federation Proceedings* 28:677, March-April 1969.

150. Effect of N-gamma-phenylpropyl-N-benzyloxy acetamide (W-1372) and clofibrate on the lipids of normal and hypercholesteremic rats, (with J. F. Douglas, G. G. Lu and B. J. Ludwig), Proceedings of the Society for Experimental Biology and Medicine 132:293-297, October 1969.
152. The effect of N-gamma-phenylpropyl-N-benzyloxy acetamide (W-1372) on experimental atherosclerosis and hypercholesteremia, (with J. F. Douglas, B. J. Ludwig and S. Margolin), Journal of Pharmacology and Experimental Therapeutics 170:371-381, December 1969.
155. The effect of N-gamma-phenylpropyl-N-benzyloxy acetamide (W-1372) and clofibrate on lipid deposits induced in rats by a high fat diet, (with J. F. Douglas, G. G. Lu and B. J. Ludwig), Federation Proceedings 29:385, March-April 1970.

ANTI-INFLAMMATORY DRUGS

160. Potential anti-inflammatory agents. Aralkoxyhydrouracils and aralkoxyhydantoin, (with L. Simet, D. B. Reisner, B. J. Ludwig and F. Dursch), Journal of Medicinal Chemistry 13:1067-1071, November 1970.
166. The pharmacological properties of 7-chloro-3,3a-dihydro-2H, 9H - isoxazolo (3,2-b) (1,3) benzoxazin-9-one, W2354, a new anti-inflammatory agent (with M. Kletzkin and H. J. Spencer), Federation Proceedings 31:578, April 1972.
169. The pharmacological properties of Seclazone (7-chloro-3,3a-dihydro-2H, 9H-isoxazolo (3,2-b) (1,3) benzoxazin-9-one, a new anti-inflammatory agent, (with H. M. Bates, W. Diamantis, K. Kletzkin, O. J. Plekss, R. D. Sofia and H. J. Spencer), Pharmacology 2:164-176, March 1973).
171. Anti-inflammatory, analgesic and antipyretic activities of W-2395, 7-chloro-3,3a-dihydro-2-methyl-2H, 9H-isoxazolo (3,2-b) (1,3)-benzoxazin-9-one, (with R. D. Sofia, W. Diamantis and M. Kletzkin), Federation Proceedings 32:751, March 1973.

174. Pharmacology of a new non-steroidal anti-inflammatory agent 7-chloro-3, 3a-dihydro-2-methyl-2H, 9H-isoxazolo (3,2-b) (1,3) benzoxazin-9-one (W-2395), (with R. D. Sofia, W. Diamantis, R. Gordon, M. Kletzkin, J. Edelson, H. Singer and J. F. Douglas), *European Journal of Pharmacology* 26:51-62, April 1974.

PHARMACOLOGY

1. Besonders hohe Wirksamkeit des Follikelhormons bei vaginaler Installation. (The particularly high efficacy of the female sex hormone on vaginal administration). *Klinische Wochenschrift* 14:1601-1602, November 9, 1935.
2. Ein Beitrag zur Bakteriophagentherapie der Zystitis. (A contribution to the treatment of cystitis by bacteriophage.) *Zentralblatt für Bakteriologie Abt. I Orig.* 137:360-362, October 6, 1936.
3. Fortgesetzte Studien über vaginale Anwendung des Follikelhormons. (Continued investigations concerning the vaginal administration of estrogenic hormone.) *Klinische Wochenschrift* 16:1428-1431, October 9, 1937.
31. The conversion of beta-erythroidine to derivatives of the desmethoxy series and some of the pharmacological properties of apo-beta-erythroidine (with G. L. Sauvage and V. Boekelheide), *Science* 109:627-628, June 24, 1949.
34. Spinal cord depressant drugs, *Pharmacological Reviews* 1(2):243-278, August 1949 and *Journal of Pharmacology and Experimental Therapeutics* 96 (Part II):243-278, August 1949.
42. A new nitrogen free, hypo-allergenic antipruritic (with O. J. Sokoloff), *Journal of the Medical Society of New Jersey* 49:23-25, January 1952.
43. Cation exchange properties of alginic acid (with B. J. Ludwig and W. T. Holfeld), *Proceedings of the Society of Experimental Biology and Medicine* 79:176-179, January 1952.
45. Medicinal uses of alginic acid (B. J. Ludwig), *Federation Proceedings* 11:322, March 1952.

48. The hydrophylic and acid binding properties of alginates with (with B. J. Ludwig and K. H. Wielich), *American Journal of Digestive Diseases* 20:39-42, February 1953.
55. The effect of W181 (1-*n*-butylamino-3-*p*-toluidino-2-propanol) on the duration of paralysis or sleep produced by various central nervous system depressants (with T. E. Lynes), *Journal of Pharmacology and Experimental Therapeutics* 110:33-34, January 1954.
57. Hypnotic action resulting from combined administration of salicylamide and acetophenetidin, *Proceedings of the Society for Experimental Biology and Medicine* 87:449-451, November 1954.
58. The analeptic action of 1-*n*-butylamino-3-*p*-toluidino-2-propanol (W181) in sleep or paralysis produced by certain central nervous system depressants (with T. E. Lynes), *Journal of Pharmacology and Experimental Therapeutics* 112:399-403, December 1954.
68. Pharmacology of the psychotherapeutic drug benactyzine (beta-diethylaminoethyl benzilate hydrochloride) (with C. D. Hendley and T. E. Lynes), *Proceedings of the Society for Experimental Biology and Medicine* 92:563-566, July 1956.
72. Some pharmacological properties of hydroxyzine (1-*p*-chlorobenzhydryl-4-(2-(2-hydroxyethoxy)-ethyl) diethyl-enediamine dihydrochloride) (with T. E. Lynes), *Journal of Pharmacology and Experimental Therapeutics* 119:163, February 1957.
73. The action of tranquilizers on brain potentials and serotonin (with G. L. Campbell, C. D. Hendley, B. J. Ludwig and T. E. Lynes), *Annals of the New York Academy of Sciences* 66(Art.3):686-694, March 1957.
83. Effect of certain tranquilizers on the reticulo endothelial system (with R. Vinegar), *Proceedings of the Society for Experimental Biology and Medicine* 102:88-90, October 1959.
86. Neuropharmacology. Transactions of the Fifth Conference, May 27, 28 and 29, 1959, Princeton, N.J., sponsored by the Josiah Macy, Jr. Foundation, New York, N.Y., pp.90-95, 194-195.
98. Pharmacology of antihypertensive agents, *New York State Journal of Medicine* 62:1580-1585, May 15, 1962.

99. Evaluation of antidepressants, *New England Journal of Medicine* 267:839, October 18, 1962.
101. Hazards of drugs in pregnancy, *British Medical Journal* 1:540, February 23, 1963.
125. The action of certain tranquilizers, antidepressants and anticholinergic drugs on hippocampal afterdischarges, (with M. Kletzkina and S. Margolin). In "Anti-Depressant Drugs," *Proceedings of the First International Symposium (Milan, 1966)*, edited by S. Garattini and M.N.G. Dukes. *Excerpta Medica*, New York 1967, pp.241-246.
129. The antidepressant action of certain tranquilizers and its reinforcement by anticholinergic drugs, (with M. Kletzkina and S. Margolin). In "Neuro-Psycho-Pharmacology," edited by H. Brill. *Excerpta Medica Foundation (New York, 1966)*, pp.1055-1060, 1967.
132. Pharmacology of anti-anxiety tranquilizers, *Chimica Therapeutica* 2:166, May-June 1967.
143. The significance of laboratory studies in the evaluation and discovery of psychoactive agents in man. *Diseases of the Nervous System* 30(Supplement):5-10, February 1969.
146. Carbamate derivatives related to meprobamate, (with B. J. Ludwig and L. S. Powell), *Journal of Medicinal Chemistry* 12:462-472, May 1969.
170. Antihypertensive action of 5-(dimethylaminoacetyl)-1,2,3,4,4a,5,6,11a-octahydromorphanthridine hydrochloride (W-2587), (with J. F. Schaefer, Jr., R. R. Loetzer, G. B. Phillips, B. J. Ludwig and M. Kletzkina), *Federation Proceedings* 32:750, March 1973.
175. The pharmacology of antianxiety (anxiolytic) agents. In "Psychopharmacological Treatment, Theory and Practice," edited by Herman C. B. Denber. *Marcel Dekker, Inc., New York, 1975*, pp.135-156.
181. Benzodiazepine enhancement of propoxyphene analgesia, (with M. E. Ellis and H. L. Johnson), *Federation Proceedings*, 36:1024, March 1977.
187. The analgesic action of combinations of propoxyphene and benzodiazepines, (with J. M. Dille and H. L. Johnson), *The International Congress of Pharmacology, IUPHAP, Abstract number 536, Pergamon Press, Paris, July 1978*, p.204.

191. 4-(p-Chlorophenylthio)-butanol (W-2719), a new non-antihistaminic drug for immediate hypersensitivity allergies, (with G. M. Fukui, B. J. Ludwig, R. D. Sofia and D. B. Reisner), *Arzneimittel Forschung-Drug Research* 29(1):912-917, June 1979.
196. Carbammati, *Farmacologia* in "Enciclopedia della Chimica," Volume II, USES Edizioni Scientifiche, Firenze 1972. pp.700-702.

BIOLOGICAL RESPONSE MODIFIERS AND IMMUNOADJUVANTS

105. Endotoxin induced resistance to infections and tolerance, (with G. Fukui,) *Proceedings of the Society for Experimental Biology and Medicine* 114:780-783, December 1963.
130. The effect of endotoxin on resistance to infection and disease. In "Advances in Pharmacology," Volume 5, edited by S. Garattini and P. A. Shore. Academic Press, New York, 1967, pp.19-46.
135. Increase of nonspecific resistance to infection by protodyne, a protein component derived from bacterial protoplasm, (with G. M. Fukui, B. J. Ludwig and J. P. Rosselet), *Proceedings of the Society for Experimental Biology and Medicine* 127:556-559, February 1968.
136. Protodyne: a proteinaceous host resistance increasing substance of bacterial origin, (with G. M. Fukui, B. J. Ludwig and J. P. Rosselet), *Federation Proceedings* 27:538, March-April 1968.
138. Effect of plasma on non-specific resistance to infection induced by endotoxin or protodyne, (with G. M. Fukui and E. Goldenbaum), *Nature (London)* 218:362-363, April 27, 1968.
141. Effect of chlorphenesin on localized hemolysis in gel assay, (with G. M. Fukui, G. C. Chandlee and E. G. Goldenbaum), *Journal of Bacteriology* 96:1133-1136, October 1968.
145. The effect of chlorphenesin on the immune response, (with G. M. Fukui, E. G. Goldenbaum, M. DeAngelo and G. C. Chandlee), *Journal of Immunology* 102:1024-1031, April 1969.

147. A non-lipopolysaccharide host resistance-increasing substance isolated from the protoplasm of gram negative bacteria, (with G. M. Fukui, B. J. Ludwig and J. P. Rosselet), *Colloques Internationaux du Centre National de la Recherche Scientifique* 174:285-295, 1969.
149. Increased host resistance to infection elicited by lipopolysaccharides from *Brucella abortus*, (with G. M. Fukui, B. J. Ludwig and J. P. Rosselet), *Proceedings of the Society for Experimental Biology and Medicine* 131:1376-1381, September 1969.
157. The increase of non-specific resistance to bacterial infections by extracts obtained from *Brucella abortus*, (with G. M. Fukui, B. J. Ludwig and J. P. Rosselet). In "International Symposium on Brucellosis," *Symposia Series in Immunobiological Standardization*, Volume 12, (Tunis, 1968), edited by R. H. Regamey, A. de Barbieri, W. Hennessen, D. Ilic and F. T. Perkins. Karger, New York, 1970, pp.269-280.
161. A proteinaceous host resistance increasing substance derived from the protoplasm of gram-negative bacteria, (with G. M. Fukui, B. J. Ludwig and J. P. Rosselet). In "International Symposium on Enterobacterial Vaccines," *Symposia Series in Immunobiological Standardization*, Volume 15, (Berne, 1969), edited by R. H. Regamey, M. Stanic and J. Ungar. Karger, New York, 1971, pp.15-28.
163. Studies on the mechanism of protodyne-induced protection against microbial infections, (with G. M. Fukui, R. H. Gustafson and J. P. Rosselet), *Proceedings of the Society for Experimental Biology and Medicine* 138:391-395, November 1971.
165. Biological study of a nontoxic water-soluble immunoadjuvant from mycobacterial cell walls (with L. Chedid, M. Parant, F. Parant and R. H. Gustafson), *Proc.Nat.Acad.Sci.U.S.A.* 69:855-858, April 1972.
167. Attenuation of certain neoplasias by chlorphenesin, (with H. J. Spencer, R. H. Runser, G. S. Tarnowski and G. Mathe), *Proceedings of the Society for Experimental Biology and Medicine* 140:1156-1161, September 1972.
172. Preparation and biological properties of water soluble adjuvant fractions from delipidated cells of *Mycobacterium smegmatis* and *Nocardia opaca*, (with A. Adam, R. Ciorbaru, J. F. Petit, E. Lederer, L. Chedid, A. Lamensans, F. Parant, M. Parant and J. P. Rosselet), *Infection and Immunity* 7:855-861, June 1973.

177. Enhancement of immunity against murine syngeneic tumors by a fraction extracted from non-pathogenic mycobacteria (with A. Lemensans, L. Chedid, E. Lederer, J. P. Rosselet, R. H. Gustafson, H. J. Spencer and B. J. Ludwig), *Proceedings of the National Academy of Science, U.S.A.* 72:3656-3660, September 1975.
190. Effects of chlorphenesin on immune reactions in vivo and in vitro, (with Jana Raskova), *Federation Proceedings* 38:1366, (Abstract 6013), March 1979.
192. Suppressive effects of chlorphenesin on lymphocyte function in mice and humans, (with D. P. Stites, G. Brecher and L. Schmidt), *Immunopharmacology* 2:39-49, 1979.
199. Protodyne: An immunomodulatory protein component, prepared from *Bacillus subtilis* (with V. Houba as first author, J. Le, J. Mauel, J. Vilcek, M. T. E. Vogels and F. M. Berger). 4th Interscience World Conference on Inflammation, Antirheumatics, Analgesics, Immunomodulators. Palexpo, Geneva, Switzerland. April 15-18, 1991. Abstract 162.
200. Protodyne: An immunomodulatory protein component, prepared from gram-positive *Bacillus subtilis* (with V. Houba as first author, J. Le, W. M. Van der Meer, J. Vilcek and F. M. Berger). Symposium on standardization of the immunopharmacology of natural and synthetic immunomodulators arranged by the International Association of Biological Standardization at Annecy, France, May 15-17, 1991. Abstract 40-O, p.68.
201. Protodyne: An immunomodulatory protein component, prepared from *Bacillus subtilis* (with V. Houba as first author, and F. M. Berger, C. A. Dinarello, A. G. Johnson, J. Le, J. Mauel, J. W. M. Van Der Meer, M. M. Philippeaux, J. Vilcek, M. T. E. Vogels). *International Journal of Immunotherapy* VIII (3):109-116, 1991.
203. Protodyne: An immunostimulatory protein component, prepared from gram-positive *Bacillus subtilis* (with V. Houba as first author, and F. M. Berger, C. A. Dinarello, A. G. Johnson, J. Le, J. Mauel, J. W. M. Van Der Meer, M. M. Philippeaux, J. Vilcek, M. T. E. Vogels). *Develop. biol. Standard.*, 77:121-128, Karger, Basel, 1992.

MICROBIOLOGY AND IMMUNOLOGY

2. Ein Beitrag zur Bakteriophagentherapie der Zystitis. (A contribution to the treatment of cystitis by bacteriophage.) Zentralblatt für Bakteriologie Abt. I Orig. 137:360-362, October 6, 1936.
4. Ueber die Möglichkeit einer lokalen Steigerung der Kurzwellenwirkung (with G. Brecher). (Concerning the local intensification of short wave effects). Wiener Klinische Wochenschrift 51:1129-1131, October 14, 1938.
5. A slide agglutination test for the exclusion and diagnosis of typhoid fever (with G. Brecher), Journal of Hygiene 39:294-297, May 1939.
6. An agglutination test for the serological diagnosis of syphilis, Journal of Pathology and Bacteriology 55:363-371, July 1943.
7. Clumping of pathogenic staphylococci in plasma, Journal of Pathology and Bacteriology 55:435-440, October 1943.
8. The sensitizing and indicator action of Victor blue and Janus green on the flocculation reaction for syphilis, British Journal of Experimental Pathology 24:252-260, December 1943.
9. The incidence and causes of discrepancies in the results of serological tests for syphilis (with P.L. Sutherland), Journal of Pathology and Bacteriology 56:237-246, April 1944.
10. A milk-borne outbreak of gastroenteritis due to Salmonella dublin (with P.L. Sutherland), British Medical Journal 1:488-490, April 8, 1944.
11. A procedure for the serological diagnosis of syphilis based on a comparative study of five modern serological tests (with G. Denton), British Journal of Venereal Diseases 20:118-123, September 1944.
14. A new non-mannite-fermenting dysentery organism of the Flexner group, Journal of Hygiene 44:116-119, April 1945.
52. The antimicrobial action of certain glycerol ethers and related compounds, (with C. V. Hubbard and B. J. Ludwig), Applied Microbiology 1:146-149, May 1953.

PENICILLIN

12. Extraction and purification of penicillin, *Nature (London)* 154:459, October 7, 1944.
13. Preparation of purified penicillin, *British Medical Journal* 1:116-117, January 27, 1945.
15. Properties, preparation and clinical application of penicillin, *Compendium of the Czechoslovak Medical Association in Great Britain* 1:3-10, June 1945.
17. The comparative value of arachis oil with beeswax and ethyl oleate with beeswax in delaying absorption of penicillin, *Quarterly Journal of Pharmacy and Pharmacology* 20:22-27, January-March 1947.
121. Selective suppression of penicillin hypersensitivity by certain phenoxy propanediols, (with G. Fukui, B. J. Ludwig and S. Margolin), *Proceedings of the Society for Experimental Biology and Medicine* 124:303-310, January 1967.
124. Two types of PCA evoking penicillin antibodies, (with G. M. Fukui, L. May, E. G. Goldenbaum and M. DeAngelo), *Bacteriological Proceedings*, 1967, p.66.
134. Suppression of penicillin induced passive cutaneous anaphylaxis reaction with phenoxypropanediols, (with G. M. Fukui), *Giornale Dell' Arteriosclerosi* 5:551-563, September-October 1967.
137. Penicillin-proteins in antibody synthesis and chlorphenesin suppression by plaque assay, (with G. Chandlee, S. Czaplicki and (with G. Fukui), *Bacteriological Proceedings*, 1968, p.66.
159. Antibiotic and hypersensitivity studies of N6-(P-chlorophenoxy lactyl)-6-amino penicillanic acid, (with G. M. Fukui, B. J. Ludwig and C. V. Hubbard). In "Progress in Antimicrobial and Anticancer Chemotherapy," *Proceedings of the Sixth International Congress of Chemotherapy*, University of Tokyo Press, Tokyo, Volume 1, 1970, pp.557-561.

PSYCHIATRY

74. The chemistry and mode of action of tranquilizing drugs, *Annals of the New York Academy of Sciences* 67 (Art. 10):685-699, May 1957.
87. Classification of psychoactive drugs according to their chemical structure and sites of action. In "Drugs and Behavior," edited by L. Uhr and J. G. Miller. John Wiley and Sons, Inc., New York, 1960, pp.86-105.
100. The treatment of anxiety, a critical review, *Journal of Neuropsychiatry* 2:98-103, December 1962.
109. The tranquilizer decade, *Journal of Neuropsychiatry* 5:403-410, October 1964.
112. Anxiety and its treatment, *Journal of the American Society of Psychosomatic Dentistry and Medicine* 12:53-64, July 1965.
116. Why we should use drugs in managing the anxious patient. In "Controversy in Internal Medicine," edited by F. J. Ingelfinger, A. S. Relman and M. Finland. Saunders, Philadelphia, 1966, pp.625-632.
119. Control of the mind, *American Journal of Pharmacy* 138:51-56, March-April 1966.
120. Evaluation of tranquilizers. The techniques and their meaning. In "Methods in Drug Evaluation," Proceedings of the International Symposium (Milano, 1965), edited by P. Mantegazza and F. Piccinini. North-Holland Publishing Company, Amsterdam, 1966, pp.218-233.
148. The effect of antianxiety tranquilizers on the behavior of normal persons, (with J. Potterfield). In "The Psychopharmacology of the Normal Human," edited by W. O. Evans and N. S. Kline. C. C. Thomas, Springfield, Illinois, 1969, pp. 38-113.
151. Mental disease and drugs affecting it, *Perspectives in Biology and Medicine* 13:31-44, Autumn 1969.
153. Drug abuse and society, (with J. Potterfield). In "Drugs and Youth," edited by J. R. Wittenborn, H. Brill, J. P. Smith and S. A. Wittenborn. C. C. Thomas, Springfield, Illinois, 1969, pp.37-43.

158. Anxiety and the discovery of the tranquilizers. In "Discoveries in Biological Psychiatry," edited by F. J. Ayd, Jr. and B. Blackwell. J. B. Lippincott Company, Philadelphia, 1970, pp.115-129.
164. The drugs of the future. In "Abstracts of the Fifth World Congress of Psychiatry, Mexico City (November 28-December 4) 1971, pp.106-107.
168. Social implication of psychotropic drugs. *Advances in Pharmacology and Chemotherapy* 10:105-118, 1972.
173. The drugs of the future. In "Proceedings of the V World Congress of Psychiatry, Mexico, D. F., 25 November-4 December 1971," edited by Fuente, Ramon de la and Weissman, Maxwell N., New York and Amsterdam, Excerpta Medica International Congress Series No. 274, 1973, pp.588-593.
176. Depression and antidepressant drugs. *Clinical Pharmacology and Therapeutics*, 18:241-248, September 1975.
178. Present status of clinical psychopharmacology. *Clinical Pharmacology and Therapeutics*, 19:725-731, June 1976.
179. Therapeutic uses of meprobamate and the propanediols. In "Drug Treatment of Mental Disorders," edited by L. L. Simpson, Raven Press, New York, pp.91-107, 1976.
180. Aminergic factors in mental illness. In "Current Developments in Psychopharmacology," 3:127-153, Spectrum Publications, Inc., New York, 1976.
182. Meprobamate and other glycol derivatives. In "Psychotherapeutic Drugs," Vol. 2, edited by E. Usdin and I. S. Forrest. Marcel Dekker, Inc., New York, pp.1089-1100, 1977.
188. Introduction: The aims and achievements of psychopharmacology. In "Principles of Psychopharmacology," edited by W. G. Clark and J. del Guidice. 2nd edition. Academic Press, New York, 1979, pp.1-7.
194. The use of antianxiety drugs. Commentary. *Clinical Pharmacology and Therapeutics* 29:291-294, March 1981.

REVIEWS AND MISCELLANEOUS WRITINGS

195. How to be happy in spite of life's vicissitudes. In "Life Stress," Volume III of Companion to the Life Sciences, Stacey B. Day, editor. Van Nostrand Reinhold Company, New York, pp.104-109, 1982.
197. James Madison Dille, Obituary. The Pharmacologist 30:31-32. 1988.
198. The "Social Chemistry" of Pharmacological Discovery: The Milltown Story. Social Pharmacology 2:(3):189-204. 1988.
202. Irving H. Page. Obituary. The Pharmacologist 34(1):34-35. 1992.
204. Lob der Tranquilizer (In Praise of Tranquilizers) in "Angsterkrankungen, Prevention und Therapie" (Anxiety disorders, prevention and therapy), Gerhard Nissen, editor, Verlag Hans Huber, Bern pp.77-79, 1995.
205. Introduction of Antianxiety Drugs. In "Towards CINP," T. A. Ban and H. Hippus, editors. J. M. Productions, Brentwood, Tennessee, pp.24-26, June 1994. Also in "A History of the CINP," T. A. Ban and O. S. Ray, editors. J. M. Productions, Brentwood, Tennessee, pp.281-283, 1996.
206. Propanediols. Half a Century of Tranquilizer Use. In "A History of the CINP," T. A. Ban and O. S. Ray, editors. J. M. Productions, Brentwood, Tennessee, pp.418-421, 1996.
207. As I Remember, in "The Rise of Psychopharmacology And The Story Of CINP," T. A. Ban, D. Healy and E. Shorter, editors. Animula Publishing House, Budapest, pp. 59-62, 1998.